[The treatment of Paget's disease using salmon thyrocalcitonin. 8 cases (author's transl)].
An open trial of synthetic salmon thyrocalcitonin was carried out in 8 cases of progressive and multifocal Paget's disease over a period of three months and at a dose of 80 MRC.U twice daily. A clinical improvement was seen in half the cases. The action was also marked upon laboratory parameters with, in particular, an average decrease in alkaline phosphatase of 51% and in urinary hydroxyproline levels of 29.4%.
D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D002116:Calcitonin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D010758:Phosphorus / Q000378:metabolism; D012474:Salmon
D010758:Phosphorus; D002116:Calcitonin; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium
Traitement de la maladie de Paget par thyrocalcitonine de saumon. 8 observations.